+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria



Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria



Expert Opinion on Investigational Drugs 27(4): 325-338



Label="INTRODUCTION">Infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) are associated with significant mortality and costs. New drugs in development to combat these difficult-to-treat infections primarily target carbapenem-resistant Enterobacteriaceae, MDR Pseudomonas aeruginosa, and MDR Acinetobacter baumannii.Label="AREAS COVERED">The authors summarize in vitro and in vivo efficacy studies, as well as available clinical trial findings, for new agents in development for treatment of infection caused by MDR-GNB. Information regarding dosage regimens utilized in clinical trials and key pharmacokinetic and pharmacodynamic considerations are provided if available. A summary of recently approved agents, delafloxacin and meropenem/vaborbactam, is also included.Label="EXPERT OPINION">The development of multiple novel agents to fight MDR-GNB is promising to help save the lives of patients who acquire infection, and judicious use of these agents is imperative once they come to market to prevent the development of resistance. The other component paramount to this field of research is implementation of effective infection control policies and carbapenem-resistant Enterobacteriaceae (CRE) carrier screening protocols to mitigate the worldwide spread of MDR-GNB. Further investigation of anti-infective synergistic combinations will also be important, as well as support for economic research to reveal the true cost-benefit of utilization of the new agents discussed herein.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065256290

Download citation: RISBibTeXText

PMID: 29611447

DOI: 10.1080/13543784.2018.1460354


Related references

Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria. Journal of Clinical Pharmacy and Therapeutics 39(3): 272-276, 2014

Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria. International Journal of Antimicrobial Agents 31(1): 80-82, 2008

Intraventricular or intrathecal colistin for the treatment of central nervous system infections caused by multidrug-resistant Gram-negative bacteria. Expert Review of Anti-Infective Therapy 12(4): 471-478, 2014

Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria. Cleveland Clinic Journal of Medicine 74(Suppl. 4): S12-S20, 2007

Increased Costs Associated with Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Bacteria Are Due Primarily to Patients with Hospital-Acquired Infections. Antimicrobial Agents and ChemoTherapy 61(3):, 2017

Association between infections caused by multidrug-resistant gram-negative bacteria and mortality in critically ill patients. World Journal of Critical Care Medicine 5(2): 111-120, 2016

Predictors of mortality in bloodstream infections caused by multidrug-resistant gram-negative bacteria: 4 years of collection. American Journal of Infection Control (): -, 2016

Epidemiology of infections caused by multidrug-resistant gram-negative bacteria in adult hospitalized patients at Siriraj Hospital. Journal of the Medical Association of Thailand 97(Suppl. 3): S35-S45, 2014

Is colistin effective in the treatment of infections caused by multidrug-resistant (MDR) or extremely drug-resistant (XDR) gram-negative microorganisms in children?. Diagnostic Microbiology and Infectious Disease 85(2): 233-238, 2016

Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens. Expert Opinion on Investigational Drugs 17(5): 749-771, 2008

Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens. Future Microbiology 9(9): 1053-1069, 2014

Linezolid New group antibacterial drug for the treatment of infections caused by gram-positive multidrug resistant bacteria. Antibiotiki i Khimioterapiya 47(2): 38-46, 2002

Nebulized colistin for treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: we still need to straighten out the dose!. Critical Care 19: 265, 2015

Ciprofloxacin in the treatment of infections caused by gentamicin-resistant gram-negative bacteria. European Journal of Clinical Microbiology 5(2): 248-251, 1986

Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: a systematic review and meta-analysis. International Journal of Antimicrobial Agents 44(6): 477-485, 2014